Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Methylene blue (USP pharmaceutical grade)

Methylene Blue (USP Pharmaceutical Grade) · also known as Methylene blue, Methylene blue, USP-grade methylene blue, Methylthioninium Chloride

Methylene blue is a potent MAO-A inhibitor, and in isolated mitochondrial systems it can transfer electrons. Its ability to bypass mitochondrial complexes and improve cognition has not been confirmed in humans. Combining it with serotonergic drugs can cause serious adverse reactions.

Typical dose: A commonly cited dose for cognitive enhancement is 0.5–1 mg/kg body weight per day. For a 70 kg adult that works out to about 35–70 mg, which does not match the commonly stated single dose of 10–30 mg. This dose is also not an established regimen for cognitive enhancement. Methylene blue is a drug with significant interactions, and its use should be assessed and managed by a clinician.
Absorption and forms: Oral absorption is fairly good and the compound is quite lipophilic. There is currently no direct human evidence on whether it crosses the blood-brain barrier and reaches effective concentrations in neurons and heart muscle. Use only USP pharmaceutical-grade product. Industrial dye grade is strictly prohibited because of the risk of heavy-metal poisoning.

Clinical uses and human evidence

Age-related cognitive decline

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Wischik 2015 · J Alzheimers Dis · RCT · n=321 — Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease
  2. Gauthier 2016 · Lancet · RCT · n=891 — Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Memory

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Rodriguez 2016 · Radiology · RCT · n=26 — Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain

Attention and focus

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Rodriguez 2016 · Radiology · RCT · n=26 — Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain

Mechanisms of action

Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)

★★★★☆Mechanism evidence: grade BPrimary target

Methylene blue is a potent MAO-A inhibitor, with a Ki of about 27 nmol/L in purified enzyme experiments. Increases in synaptic neurotransmitters in humans have not been measured directly, but drug labeling already warns of serotonin syndrome risk when it is combined with serotonergic drugs.

References (2)
  1. Ramsay et al. 2007 · Purified human enzyme study: methylene blue inhibits MAO-A, Ki about 27 nmol/L
  2. US prescribing information · Clinical warning: use with serotonergic drugs can cause serotonin syndrome

Mitochondrial electron transport chain carriers and oxidative phosphorylation coupling

★★☆☆☆Mechanism evidence: grade DPrimary target

In isolated mitochondrial systems, methylene blue can transfer electrons, and in theory it could sustain electron transport when a complex is blocked. However, some studies have not reproduced bypass rescue after complex III is blocked. Whether oral dosing produces the same bypass effect in humans is unresolved.

References (2)
  1. Lin et al. 2012 · Rat and isolated mitochondria study: observed brain metabolic changes and electron-transport effects in isolated mitochondria
  2. Gureev et al. 2019 · Mouse isolated brain mitochondria study: could not reproduce bypass rescue after complex III block

Cholinergic neurotransmission (ACh precursor supply and AChE inhibition)

★★☆☆☆Mechanism evidence: grade DSecondary target

In vitro, methylene blue can inhibit cholinesterase and bind muscarinic receptors. These results come from ex vivo experiments. There is no evidence that usual oral doses raise acetylcholine in the human hippocampus or improve memory.

References (1)
  1. 1997 · Ex vivo experiment: methylene blue can inhibit cholinesterase and bind muscarinic receptors

Safety and drug interactions

Absolute contraindication: never combine with any SSRI or SNRI antidepressant, a monoamine oxidase inhibitor (MAOI), or serotonergic drugs such as tramadol, linezolid or meperidine. Methylene blue has strong MAO-A inhibitory activity and may trigger fatal serotonin syndrome. Contraindicated in people with G6PD deficiency (favism) because of the risk of hemolysis. Contraindicated in pregnancy because of fetal toxicity. People with impaired kidney function, or who take other medicines, should have interactions assessed before use. Blue-green urine is a normal effect of its metabolism and excretion.

Serotonin excess risk

A potent MAO-A inhibitor that slows serotonin breakdown. Each of these raises serotonin levels in the brain. Taking two or more together carries a risk of serotonin syndrome, which causes agitation, sweating, a fast heartbeat, muscle twitching and fever. In severe cases it can be life-threatening.

With SSRIs, SNRIs and other serotonergic drugs Do not combine

Sertraline, fluoxetine, paroxetine, venlafaxine, duloxetine, tramadol, triptans (migraine drugs)

Combining methylene blue with this class of drugs can cause severe serotonin syndrome. Fatal cases have been reported, so the two must never be combined.

With MAO inhibitors Do not combine

Phenelzine, selegiline, rasagiline, linezolid

Methylene blue is itself an MAO inhibitor, so combining it with another MAOI can cause fatal serotonin syndrome.

With Isoniazid High risk

Isoniazid (for tuberculosis treatment or preventive treatment of latent TB)

Isoniazid has some monoamine oxidase inhibitory activity, and combining it with methylene blue may increase the risk of serotonin syndrome. Do not take methylene blue without medical advice while you are on isoniazid.

Open in the interactive app ›